Streetbeat News

Analyst Ratings

CATY

Wedbush analyst David Chiaverini maintains an Outperform rating on Cathay General (NASDAQ:CATY) but lowers the price target from $42 to $40.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:50 pm

AN

BMY

FSR

IRDM

PBR

Jim Cramer, on CNBC's 'Mad Money Lightning Round', recommended selling Petróleo Brasileiro S.A. - Petrobras (PBR) and Fisker Inc. (FSR). He expressed concerns about AutoNation, Inc. (AN) and Bristol-Myers Squibb Company (BMY), but did not recommend selling them. He also mentioned that Iridium Communications Inc. (IRDM) is expected to lose money.

Portfolio Pulse from Lisa Levin

October 24, 2023 | 12:47 pm

HOPE

Wedbush analyst David Chiaverini has maintained a Neutral rating on Hope Bancorp (NASDAQ:HOPE) and lowered the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:42 pm

GOOGL

Seaport Global analyst Aaron Kessler has initiated coverage on Alphabet (NASDAQ:GOOGL) with a Neutral rating.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:39 pm

WEX

Morgan Stanley analyst James Faucette has maintained an Equal-Weight rating on WEX (NYSE:WEX) and raised the price target from $200 to $205.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:39 pm

WIX

Seaport Global analyst Aaron Kessler has initiated coverage on Wix.com (NASDAQ:WIX) with a Buy rating and a price target of $103.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:37 pm

TMO

Morgan Stanley analyst Tejas Savant has maintained an Overweight rating on Thermo Fisher Scientific (NYSE:TMO) but lowered the price target from $640 to $600.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:35 pm

MGTX

MeiraGTx Holdings plc (NASDAQ:MGTX), a clinical stage gene therapy company, announced that it will present eight posters and one oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress. The presentations will cover a range of topics including preclinical efficacy of gene therapy for ALS, results of a phase 1 study of gene therapy for radiation-induced xerostomia, and development of alternatives to Triton X-100 cell lysis for AAV2, AAV5 and AAV8 primary recovery.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:35 pm

PACB

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) and lowered the price target from $13 to $10.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:34 pm

LGVN

Longeveron Inc. (NASDAQ:LGVN) has been featured in a broadcast via NetworkNewsAudio, highlighting the positive top-line results from its Phase 2a trial of Lomecel-B™ for the treatment of mild Alzheimer's disease. The company's CEO, Wa'el Hashad, stated that these results validate the safety and therapeutic potential of Lomecel-B™ and provide a foundation for additional clinical trials. The company is also progressing with its Phase 2 ELPIS II trial in HLHS and Phase 2 program in Aging-related Frailty in Japan.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:33 pm